Glaxosmithkline Share News (GSK)

London midday: UK markets lack direction as US budget impasse persists

After a slow start, the FTSE 100 had erased losses by midday on Friday but markets remain subdued as stocks struggle for direction in the absence of economic news and ongoing political uncertainty in the States. Since the partial shutdown of the US government has extended into its fourth day, gove

Broker snap: Panmure upbeat about GSK despite negative Eli Lilly readacross

Shares in GlaxoSmithKline (GSK) edged lower on Friday due to the possible negative readacross from US pharmaceuticals peer Eli Lilly, which warned about headwinds to its revenues in 2014. Nevertheless, Panmure Gordon maintained its upbeat stance on London-listed GSK, saying it would use any weaknes

DIRECTOR DEALINGS: GlaxoSmithKline Directors Allocated Shares

DIRECTOR DEALINGS: GlaxoSmithKline Executive Donates Shares To Charity

London close: Stocks at one-month low on looming US shutdown

Stocks were firmly lower on Monday as risk appetite was reduced in the face of a looming partial shutdown of the US government after a weekend of no progress in Washington. Political instability in Italy also dampened the mood today as well as disappointing economic data from China, with falls in t

CORRECTED-UPDATE 1-Bumpy road won't deter Sanofi's push into emerging markets

(Corrects the last paragraph to say GlaxoSmithKline's China sales expected to slow) * Continues to look for M&A opportunities in emerging markets * Pharma firms should support China's efforts to curb corruption By Sumeet Chatterjee MUMBAI, Sept 30 (Reuters) - French drugma

FTSE 100 movers: Miners weigh heavily after Chinese data disappoints

Mining stocks declining sharply today on the back of the disappointing data from the world's top metals user, China. Fresnillo, Anglo American, Antofagasta, Glencore Xstrata and Rio Tinto were all falling sharply. China´s manufacturing sector purchasing managers´ index (PMI) for the month of Septe

GSK sells thrombosis drug brands to Aspen Pharmacare

GlaxoSmithKline (GSK) is selling its thrombosis drug brands and a related factory to South Africa's biggest generic drug maker Aspen Pharmacare for 700m pounds. The drug company has decided to let go of its Arixtra and Fraxiparine brands after experiencing falling sales. GSK said the disposal wou

UPDATE 1-GSK sells thrombosis drugs to Aspen for $1 bln

LONDON, Sept 30 (Reuters) - Britain's biggest drugmaker GlaxoSmithKline agreed the 700 million pounds ($1.13 billion) sale of its thrombosis drug brands and a related factory to Aspen Pharmacare, as part of its strategy to focus on growth products. The company said on Monday the divestment

Aspen agrees to buy GSK drugs for $967 million

JOHANNESBURG, Sept 30 (Reuters) - South Africa's Aspen Pharmacare said on Monday it had agreed to a price of 600 million pounds ($967 million) to buy thrombosis drugs and a factory from shareholder GlaxoSmithKline. Aspen and Britain's Glaxo first announced the deal in June.

GSK agrees 700 mln stg sale of thrombosis treatments

LONDON, Sept 30 (Reuters) - British pharmaceutical firm GlaxoSmithKline (GSK) said on Monday it agreed to sell its thrombosis treatment brands and related manufacturing facility to South Africa's Aspen for 700 million pounds ($1.13 billion). The company said the divestment, which will earn

GlaxoSmithKline Sells Thrombosis Drugs To Aspen Group

UPDATE 1-INSIGHT-How new cancer drugs can skip randomized trials

By Julie Steenhuysen and Ben Hirschler CHICAGO/LONDON, Sept 26 (Reuters) - In 2006 when doctors started testing a melanoma treatment made by Roche Holding AG on patients, they were used to facing slim odds - about one in eight - that the tumors would shrink on chemotherapy. This time, they

AstraZeneca CEO gets two cheers after first year in job

* Soriot's bolt-on M&A strategy helps fill strategic gaps * No quick fix as patent losses set to shrink sales, profits * Heavy science focus good for staff morale at drugmaker By Ben Hirschler LONDON, Sept 30 (Reuters) - Fixing ailing drugmaker AstraZeneca remains a work i

Sanofi starts work on $95 mln Algerian plant, biggest in Africa

PARIS, Sept 26 (Reuters) - French drugmaker Sanofi has started construction of a new 70 million-euro ($95 million) plant in Algeria that will be its largest industrial site in Africa, the company said on Thursday. Sanofi, the international drug company with the biggest sales in Africa, alr